The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …

Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR), were the first molecularly targeted agents to become …

Introduction: The epidermal growth factor receptor (EGFR) and its family members are
involved in many aspects of tumor biological processes. Aberrant activation of the EGFR …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been
established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell …

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here,
we present an update on new controversies and conclusions regarding the disease …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …

Lung cancer continues to be a major health problem and the most common cancer-related
mortality worldwide with about 80%–85% patients suffering from nonsmall cell lung cancer …

The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …